IMNN · Imunon, Inc.

Imunon reported significant clinical and financial progress for the year ended December 31, 2025. The company achieved a notable reduction in net loss to $14.5 million, or $6.83 per share, compared to a net loss of $18.6 million, or $16.94 per share, in the prior year. This improvement was driven by a 23% decrease in operating expenses to $14.7 million. Research and development costs fell 33% to $7.8 million, primarily due to lower costs associated with the completed Phase 2 OVATION 2 Study and the PlaCCine DNA vaccine Phase 1 trial, which offset start-up costs for the pivotal Phase 3 OVATION 3 study. General and administrative expenses decreased 8% to $6.9 million due to headcount reductions.

The most material development pertains to the final data from the Phase 2 OVATION 2 clinical trial for IMNN-001 in advanced ovarian cancer. The company reported a median overall survival increase of 14.7 months (45.1 vs. 30.4 months) for patients treated with IMNN-001 plus standard of care chemotherapy compared to chemotherapy alone. Furthermore, patients receiving IMNN-001 with chemotherapy and PARP inhibitors achieved a median overall survival increase of 24.2 months. Management highlighted that IMNN-001 is the first frontline immunotherapy to demonstrate potential for a clinically meaningful overall survival benefit in this indication. Enrollment in the Phase 3 OVATION 3 study is currently ahead of plan.

Financially, net cash used in operating activities decreased to $13.9 million from $18.9 million in 2024. Cash provided by financing activities totaled $17.1 million, derived from two offerings and the company’s at-the-market equity facility. The company ended the year with $8.8 million in cash and cash equivalents. Subsequent to the year-end, the company announced a strategic reorganization in February 2026 to reduce operating expenses and focus resources on the Phase 3 OVATION 3 trial.